The appointment of Ken James (formerly SVP, GSK Healthcare R&D) to the Board of Futura Medical represents a timely step by the company, supporting the commercialisation of its strong portfolio of OTC and prescription products. We continue to expect exciting newsflow ahead: first regulatory approval of CSD500 following a successful shelf life extension project and headline data from the clinical trial of MED2002 are both expected in Q2 2016, and a near-term commercial deal for a topical pain reli ....
